News Releases

<< Back
Nov 22, 2017

SCYNEXIS to Present at the 29th Annual Piper Jaffray Healthcare Conference

JERSEY CITY, N.J., Nov. 22, 2017 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present at the 29th Annual Piper Jaffray Healthcare Conference at the Lotte New York Palace Hotel on Tuesday, November 28, 2017 at 1:00 p.m. ET.

A live webcast will be available on the investors section of the Company's website: A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation.

SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. The Company's lead product candidate, SCY-078, is the first representative of a novel intravenous and oral triterpenoid antifungal family and is in Phase 2 clinical development for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections.  For more information, visit


Media Relations
Cammy Duong
MacDougall Biomedical Communications
Tel: 781-591-3443

Investor Relations
Susan Kim
Argot Partners
Tel: 212-203-4433


View original content: